581 related articles for article (PubMed ID: 24349321)
1. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
2. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
3. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
5. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.
Kokontis JM; Lin HP; Jiang SS; Lin CY; Fukuchi J; Hiipakka RA; Chung CJ; Chan TM; Liao S; Chang CH; Chuu CP
PLoS One; 2014; 9(10):e109170. PubMed ID: 25271736
[TBL] [Abstract][Full Text] [Related]
6. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
9. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A; O'Malley K; Wang Z; Raj GV; Defranco DB; Hammes SR
J Biol Chem; 2010 Sep; 285(37):28787-95. PubMed ID: 20628053
[TBL] [Abstract][Full Text] [Related]
10. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
11. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
12. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
15. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
16. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
[TBL] [Abstract][Full Text] [Related]
17. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC
J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492
[TBL] [Abstract][Full Text] [Related]
18. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
